Adaptive approaches to licensing represent an important evolutionary path for drug development, regulation, and learning that can benefit all parties – patients, payers, providers, regulators and drug developers. They may also significantly improve both patient outcomes and the timeline and cost of bringing a new drug to market. But they will also require unprecedented cooperation among various stakeholders. Learn how an international consortium is making great strides – sparking dialogue around adaptive licensing approaches, defining a workable toolkit and collaborative partnerships, and evaluating drug programs with the potential to establish the first international pilot in 2013.

Learning Objectives:

  • Explain the concept of adaptive approaches to licensing and what it aims to achieve
  • Review the work of an international consortium exploring adaptive approaches to licensing
  • Discuss opportunities and challenges to implementation of adaptive approaches to licensing

Ability Level: Intermediate

Session ID: 1927

myBIO Chatter

Speakers (3)

User Richard Barker Director CASMI
User Robyn Lim Senior Science Advisor Health Canada
User Ken Oye Professor MIT

Moderators (1)

User Thomas Unger Executive Director Pfizer Inc.

Who's Attending (1)

See all